Soleil Boughton Sells 3,458 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,458 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $28.33, for a total transaction of $97,965.14. Following the sale, the insider owned 310,506 shares of the company’s stock, valued at approximately $8,796,634.98. The trade was a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Trading Down 3.2%

NYSE:HIMS traded down $0.91 on Thursday, hitting $27.77. The stock had a trading volume of 12,055,111 shares, compared to its average volume of 25,338,594. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The stock has a market cap of $6.48 billion, a price-to-earnings ratio of -44.08 and a beta of 2.42. The company has a fifty day moving average price of $31.89 and a two-hundred day moving average price of $26.66. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $65.30.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s quarterly revenue was up 38.2% on a year-over-year basis. During the same period last year, the company earned $0.17 EPS.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Corient Private Wealth LP boosted its position in shares of Hims & Hers Health by 38.3% during the second quarter. Corient Private Wealth LP now owns 22,727 shares of the company’s stock worth $788,000 after buying an additional 6,288 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Hims & Hers Health in the second quarter valued at $1,030,000. California State Teachers Retirement System raised its holdings in shares of Hims & Hers Health by 3,404.9% in the 2nd quarter. California State Teachers Retirement System now owns 8,000,068 shares of the company’s stock valued at $277,362,000 after buying an additional 7,771,816 shares during the period. Ameritas Advisory Services LLC raised its holdings in shares of Hims & Hers Health by 12.8% in the 2nd quarter. Ameritas Advisory Services LLC now owns 17,965 shares of the company’s stock valued at $623,000 after buying an additional 2,045 shares during the period. Finally, Compass Financial Management LLC acquired a new position in Hims & Hers Health during the 2nd quarter worth about $50,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims raised its 2026 revenue outlook after second-quarter revenue increased 38.2% year over year to approximately $753 million, exceeding analysts’ expectations. Growth in weight-loss services, international markets and artificial-intelligence initiatives provides potential support for the long-term story. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
• Neutral Sentiment: Brokerage sentiment remains mixed, with HIMS receiving a consensus “Hold” rating. Analysts point to continued platform growth but also cite margin pressure and uncertainty surrounding FDA and regulatory matters. Hims & Hers Health Receives Consensus Rating of Hold
• Negative Sentiment: Multiple law firms announced or promoted securities class actions covering investors who purchased HIMS securities from August 4, 2025, through July 29, 2026. The lawsuits generally follow the stock’s sharp decline after the Federal Trade Commission’s complaint and allege that Hims made misleading statements or failed to disclose material risks. Investors have until November 2, 2026, to seek appointment as lead plaintiff. Kessler Topaz Announces HIMS Securities Fraud Class Action
• Negative Sentiment: The underlying allegations include sharing consumers’ protected health information with third-party advertising platforms and charging customers for prescriptions soon after intake, potentially before a meaningful provider consultation. Plaintiffs claim these practices could lead to regulatory scrutiny, penalties, legal expenses and reputational damage. The allegations have not been proven in court. Holzer & Holzer HIMS Investor Alert
• Negative Sentiment: Despite strong sales, Hims reported a second-quarter loss of $0.37 per share versus the consensus estimate of a $0.05 loss, while net loss and margin contraction highlighted the cost of funding rapid expansion. HIMS Raises 2026 Revenue Outlook Despite Loss

Analyst Ratings Changes

A number of equities research analysts have commented on HIMS shares. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Bank of America upped their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research note on Friday, May 22nd. Finally, Truist Financial lifted their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research report on Monday, August 24th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $32.50.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.